Back to top

Kodiak enrolls first patients in phase 3 ALTO trial evaluating KSI-501

Kodiak Sciences (KOD) announces the first patients have been enrolled in the global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Kodiak Sciences Inc. (KOD)